[1]周立　 芮静安　 王少斌　 陈曙光　 曲强.尿激酶型纤溶酶原激活剂(uPA)和其受体(uPAR)在肝细胞癌的表达及其临床和病理意义[J].中国微创外科杂志,2002,02(6):422-423.
点击复制

尿激酶型纤溶酶原激活剂(uPA)和其受体(uPAR)在肝细胞癌的表达及其临床和病理意义()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
02
期数:
2002年6期
页码:
422-423
栏目:
基础研究
出版日期:
2002-12-31

文章信息/Info

Title:
Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in hepatocellular carcinoma and its clinical and pathological significance
作者:
周立　 芮静安　 王少斌　 陈曙光　 曲强
北京协和医院基本外科,北京,100032
关键词:
尿激酶型纤溶酶原激活剂 尿激酶型纤溶酶原激活剂受体 肝细胞癌
分类号:
R735.7;R730.21
文献标志码:
A
摘要:
目的研究尿激酶型纤溶酶原激活剂(uPA)和其特异性受体(uPAR)在肝细胞癌(HCC)的表达及其临床和病理意义. 方法应用免疫组织化学和酶联免疫吸附法(ELISA)检测uPA和uPAR在HCC和非癌组织中的表达,并与临床及病理指标相联系. 结果 HCC中uPA和uPAR的阳性表达率分别为75.0%(12/16)和68.8%(1/16).在进展性和侵袭性肿瘤与非进展性和非侵袭性肿瘤间uPA和uPAR阳性率无显著性差异(P＞0.05).阳性染色主要位于癌细胞和基质细胞胞浆且主要位于癌侵犯的边缘.非癌组织仅见少量阳性染色细胞,对照组无特异性阳性染色.在ELISA中,癌与非癌组织uPA抗原水平分别为(4.23±0.57)ng/mg蛋白和(1.26±0.14)ng/mg蛋白,uPAR抗原水平分别为(4.25±0.21)ng/mg蛋白和(3.15±0.23)ng/mg蛋白,有显著性差异(t=18.963,P=0.000;t=13.693,P=0.000).且进展性和侵袭性肿瘤中其抗原水平显著高于非进展性和非侵袭性肿瘤(P＜0.05). 结论 uPA和uPAR在肝细胞癌表达较高并与其进展和侵袭密切关联.

参考文献/References:

［1］Knoop A, Andreasen PA, Andersen JA, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer, 1998, 77:932-940.
［2］Suzuki S, Hayashi Y, Wang Y, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut, 1998, 43:798-805.
［3］Nakajima M, Chop AM. Tumor invasion and extracellular matrix degradative enzyme: regulation of activity by organ factors. Semin Cancer Biol, 1991, 2:115-127.
［4］Jankun J, Merrick HW, Goldblatt PJ. Expresion and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Cell Biochem, 1993, 53:135-144.
［5］Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem, 1991, 266:12752-12758.
［6］Miyake H, Hara I, Yamanaka K, et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol, 1999, 14:535-541.

更新日期/Last Update: 2014-07-31